Eloxx Pharmaceuticals, Inc. (ELOX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -36.06 Million USD | 45.95% |
| 2021 | -66.72 Million USD | -92.98% |
| 2020 | -34.57 Million USD | 32.03% |
| 2019 | -50.87 Million USD | -7.82% |
| 2018 | -47.18 Million USD | -122.42% |
| 2017 | -21.21 Million USD | -265.99% |
| 2016 | -5.79 Million USD | 29.89% |
| 2015 | -8.26 Million USD | 54.23% |
| 2014 | -18.06 Million USD | -95.81% |
| 2013 | -9.22 Million USD | -50.68% |
| 2012 | -6.12 Million USD | -20.85% |
| 2011 | -5.06 Million USD | 30.3% |
| 2010 | -7.26 Million USD | 45.69% |
| 2009 | -13.38 Million USD | -133.7% |
| 2008 | -5.72 Million USD | -24.46% |
| 2007 | -4.6 Million USD | -41.51% |
| 2006 | -3.25 Million USD | 1.91% |
| 2005 | -3.31 Million USD | -11.28% |
| 2004 | -2.97 Million USD | 20.07% |
| 2003 | -3.72 Million USD | -80.37% |
| 2002 | -2.06 Million USD | -6.54% |
| 2001 | -1.93 Million USD | -3.33% |
| 2000 | -1.87 Million USD | 23.23% |
| 1999 | -2.44 Million USD | -109.15% |
| 1998 | -1.16 Million USD | -11168.51% |
| 1997 | -10.37 Thousand USD | -32.83% |
| 1996 | -7810.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | -4.34 Million USD | 30.32% |
| 2023 Q3 | -3.59 Million USD | 17.25% |
| 2023 Q1 | -6.23 Million USD | 1.41% |
| 2022 Q2 | -10.61 Million USD | 8.62% |
| 2022 Q4 | -6.31 Million USD | 15.84% |
| 2022 Q3 | -7.5 Million USD | 29.29% |
| 2022 FY | -36.06 Million USD | 45.95% |
| 2022 Q1 | -11.62 Million USD | 3.89% |
| 2021 Q4 | -12.09 Million USD | -22.31% |
| 2021 FY | -66.72 Million USD | -92.98% |
| 2021 Q1 | -8.69 Million USD | -41.9% |
| 2021 Q2 | -36.05 Million USD | -314.75% |
| 2021 Q3 | -9.88 Million USD | 72.59% |
| 2020 Q1 | -13.94 Million USD | -19.88% |
| 2020 Q4 | -6.12 Million USD | 7.41% |
| 2020 Q3 | -6.61 Million USD | 16.1% |
| 2020 FY | -34.57 Million USD | 32.03% |
| 2020 Q2 | -7.88 Million USD | 43.45% |
| 2019 FY | -50.87 Million USD | -7.82% |
| 2019 Q1 | -11.91 Million USD | 15.04% |
| 2019 Q2 | -14.44 Million USD | -21.25% |
| 2019 Q3 | -12.87 Million USD | 10.89% |
| 2019 Q4 | -11.63 Million USD | 9.65% |
| 2018 Q1 | -8.59 Million USD | 0.0% |
| 2018 FY | -47.18 Million USD | -122.42% |
| 2018 Q3 | -11.16 Million USD | 16.75% |
| 2018 Q2 | -13.4 Million USD | -56.05% |
| 2018 Q4 | -14.02 Million USD | -25.68% |
| 2017 Q1 | -2.06 Million USD | -161.58% |
| 2017 Q3 | -1.26 Million USD | 36.87% |
| 2017 FY | -21.21 Million USD | -265.99% |
| 2017 Q2 | -2 Million USD | 2.86% |
| 2016 Q3 | -933.57 Thousand USD | 19.01% |
| 2016 Q1 | -3.07 Million USD | 20.14% |
| 2016 Q2 | -1.15 Million USD | 62.57% |
| 2016 Q4 | -789.83 Thousand USD | 15.4% |
| 2016 FY | -5.79 Million USD | 29.89% |
| 2015 Q3 | -180.74 Thousand USD | 80.07% |
| 2015 Q2 | -906.77 Thousand USD | 26.1% |
| 2015 Q4 | -3.85 Million USD | -2033.1% |
| 2015 Q1 | -1.22 Million USD | 88.58% |
| 2015 FY | -8.26 Million USD | 54.23% |
| 2014 Q4 | -10.74 Million USD | -107.3% |
| 2014 Q1 | -2.14 Million USD | -32.55% |
| 2014 Q3 | -5.18 Million USD | -41.07% |
| 2014 Q2 | -3.67 Million USD | -71.17% |
| 2014 FY | -18.06 Million USD | -95.81% |
| 2013 Q3 | -1.78 Million USD | 7.58% |
| 2013 FY | -9.22 Million USD | -50.68% |
| 2013 Q4 | -1.61 Million USD | 9.23% |
| 2013 Q2 | -1.93 Million USD | -130.77% |
| 2013 Q1 | -836.58 Thousand USD | 34.12% |
| 2012 Q2 | -1.43 Million USD | -35.66% |
| 2012 Q4 | -1.26 Million USD | 39.11% |
| 2012 FY | -6.12 Million USD | -20.85% |
| 2012 Q3 | -2.08 Million USD | -44.93% |
| 2012 Q1 | -1.06 Million USD | 30.57% |
| 2011 Q3 | -1.03 Million USD | 61.69% |
| 2011 Q2 | -2.71 Million USD | -93.0% |
| 2011 Q1 | -1.4 Million USD | -23.63% |
| 2011 Q4 | -1.52 Million USD | -47.03% |
| 2011 FY | -5.06 Million USD | 30.3% |
| 2010 Q4 | -1.13 Million USD | 43.61% |
| 2010 FY | -7.26 Million USD | 45.69% |
| 2010 Q3 | -2.01 Million USD | 67.53% |
| 2010 Q2 | -6.2 Million USD | -17.45% |
| 2010 Q1 | -5.28 Million USD | -210.17% |
| 2009 Q2 | -1.58 Million USD | -19.39% |
| 2009 FY | -13.38 Million USD | -133.7% |
| 2009 Q4 | -1.7 Million USD | -800.0% |
| 2009 Q3 | -189.29 Thousand USD | 88.09% |
| 2009 Q1 | -1.33 Million USD | 18.03% |
| 2008 FY | -5.72 Million USD | -24.46% |
| 2008 Q3 | -1.18 Million USD | -34.16% |
| 2008 Q4 | -1.62 Million USD | -37.49% |
| 2008 Q2 | -880.6 Thousand USD | 56.92% |
| 2008 Q1 | -2.04 Million USD | -57.89% |
| 2007 FY | -4.6 Million USD | -41.51% |
| 2007 Q4 | -1.29 Million USD | -238.88% |
| 2007 Q1 | -801.31 Thousand USD | 29.44% |
| 2007 Q2 | -714.27 Thousand USD | 10.86% |
| 2007 Q3 | -382.04 Thousand USD | 46.51% |
| 2006 Q4 | -1.13 Million USD | -89.13% |
| 2006 Q3 | -600.46 Thousand USD | 23.64% |
| 2006 Q2 | -786.33 Thousand USD | -9.61% |
| 2006 Q1 | -717.42 Thousand USD | 21.51% |
| 2006 FY | -3.25 Million USD | 1.91% |
| 2005 Q3 | -897.12 Thousand USD | -90.2% |
| 2005 Q2 | -471.67 Thousand USD | 48.11% |
| 2005 FY | -3.31 Million USD | -11.28% |
| 2005 Q4 | -914 Thousand USD | -1.88% |
| 2005 Q1 | -908.9 Thousand USD | -40.86% |
| 2004 Q2 | -462.6 Thousand USD | -10.93% |
| 2004 Q1 | -417.01 Thousand USD | 47.76% |
| 2004 Q3 | -723.62 Thousand USD | -56.42% |
| 2004 Q4 | -645.23 Thousand USD | 10.83% |
| 2004 FY | -2.97 Million USD | 20.07% |
| 2003 Q2 | -473.61 Thousand USD | 8.16% |
| 2003 Q3 | -1.4 Million USD | -195.7% |
| 2003 FY | -3.72 Million USD | -80.37% |
| 2003 Q4 | -798.18 Thousand USD | 43.01% |
| 2003 Q1 | -515.68 Thousand USD | 8.31% |
| 2002 Q1 | -482.82 Thousand USD | 20.16% |
| 2002 Q3 | -514.63 Thousand USD | -46.8% |
| 2002 Q4 | -562.41 Thousand USD | -9.28% |
| 2002 FY | -2.06 Million USD | -6.54% |
| 2002 Q2 | -350.55 Thousand USD | 27.39% |
| 2001 Q3 | -501.27 Thousand USD | -20.96% |
| 2001 Q2 | -414.42 Thousand USD | 7.68% |
| 2001 Q4 | -604.76 Thousand USD | -20.65% |
| 2001 FY | -1.93 Million USD | -3.33% |
| 2001 Q1 | -448.88 Thousand USD | 11.53% |
| 2000 FY | -1.87 Million USD | 23.23% |
| 2000 Q3 | -506.29 Thousand USD | 18.69% |
| 2000 Q4 | -507.38 Thousand USD | -0.22% |
| 2000 Q1 | -827.42 Thousand USD | -65.48% |
| 2000 Q2 | -622.68 Thousand USD | 24.74% |
| 1999 Q4 | -500 Thousand USD | 0.0% |
| 1999 FY | -2.44 Million USD | -109.15% |
| 1998 FY | -1.16 Million USD | -11168.51% |
| 1997 FY | -10.37 Thousand USD | -32.83% |
| 1996 FY | -7810.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -4636.545% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -317.806% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -17.288% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 70.942% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -124.313% |
| Better Therapeutics, Inc. | -39.76 Million USD | 9.293% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -91.164% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -96.241% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -0.709% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 68.51% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -1504.129% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 51.755% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 38.958% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -502.261% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -69.367% |
| Molecular Templates, Inc. | -8.12 Million USD | -343.932% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -137.627% |
| NexImmune, Inc. | -32.34 Million USD | -11.503% |
| Orgenesis Inc. | -55.36 Million USD | 34.855% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -42.758% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -46127.104% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -97.187% |
| Scopus BioPharma Inc. | -11.6 Million USD | -210.642% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 93.704% |
| Statera Biopharma, Inc. | -174.4 Million USD | 79.321% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -905.156% |
| Trevena, Inc. | -40.28 Million USD | 10.484% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -63245.277% |
| Vaccinex, Inc. | -20.25 Million USD | -78.09% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -2950.895% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 29.365% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -363.728% |